Alectinib (INN), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). It blocks the activity of anaplastic lymphoma kinase (ALK). It is taken by mouth. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
The most common side effects include constipation, muscle pain and edema (swelling) including of the ankles and feet, the face, the eyelids and the area around the eyes.
Alectinib was approved for medical use in Japan in 2014, the United States in 2015, Canada in 2016, Australia in 2017, the European Union in 2017, and the United Kingdom in 2021. |
Read full article at Wikipedia
|
InChI=1S/C20H20BrN3O2S.2ClH/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20;;/h1-10,12,15,22,24H,11,13-14H2;2*1H |
GELOGQJVGPIKAM-UHFFFAOYSA-N |
Cl.Cl.[H]C(CNCCNS(=O)(=O)C1=CC=CC2=C1C=CN=C2)=C([H])C1=CC=C(Br)C=C1 |
|
EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of cAMP-dependent protein kinase (EC 2.7.11.11).
|
|
View more via ChEBI Ontology
Outgoing
|
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide dihydrochloride
(CHEBI:131488)
has part
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide(2+)
(CHEBI:131489)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide dihydrochloride
(CHEBI:131488)
has role
EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
(CHEBI:85094)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide dihydrochloride
(CHEBI:131488)
is a
hydrochloride
(CHEBI:36807)
|
|
5-[(2-{[3-(4-bromophenyl)prop-2-en-1-yl]azaniumyl}ethyl)sulfamoyl]isoquinolin-2-ium dichloride
|
N-(2-{[3-(4-bromophenyl)prop-2-en-1-yl]amino}ethyl)isoquinoline-5-sulfonamide dihydrochloride
|
H-89 dihydrochloride
|
ChEBI
|
H-89 hydrochloride
|
ChEBI
|
H-89·2HCl
|
ChEBI
|
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide hydrochloride
|
ChEBI
|
8457569
|
Reaxys Registry Number
|
Reaxys
|
26093361
|
PubMed citation
|
Europe PMC
|
|